Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL243552 | 0.97 | LMNA (0.40) | LMNAFDPSCA2ALDH1A1BLM | |
| SCHEMBL695544 | 0.94 | LMNA (0.38) | LMNAFDPSCA2ALDH1A1BLM | |
| SCHEMBL553541 | 0.94 | LMNA (0.38) | LMNAFDPSCA2ALDH1A1BLM | |
| Methylamine SCHEMBL17749558 | 0.91 | FDPS (0.41) | LMNAFDPSCA2ALDH1A1 | |
| Tetramethylammonium Ion SCHEMBL238777 | 0.88 | LMNA (0.35) | LMNAFDPSCA2 | |
| SCHEMBL571123 | 0.85 | LMNA (0.36) | LMNAFDPSCA2ALDH1A1BLM | |
| SCHEMBL27947422 | 0.84 | PGK1 (0.35) | LMNAFDPS | |
| SCHEMBL3817093 | 0.82 | LMNA (0.41) | LMNAFDPSCA2ALDH1A1 | |
| SCHEMBL27801260 | 0.81 | LMNA (0.38) | LMNAFDPSCA2ALDH1A1BLM | |
| SCHEMBL21815536 | 0.80 | LMNA (0.33) | LMNAFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108456194-B | Triazole antibacterial derivative, and pharmaceutical composition and application thereof | 武汉朗来科技发展有限公司 | 2021-06-22 | — | — | CN | disclosed |
| CN-107033186-B | Posaconazole derivatives, pharmaceutical compositions and uses thereof | 武汉朗来科技发展有限公司 | 2020-06-09 | — | — | CN | disclosed |
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| EP-2601177-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AstraZeneca AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| WO-2012017251-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| WO-2002042283-A1 | IMPROVED PROCESS FOR WATER SOLUBLE AZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-05-30 | — | — | WO | disclosed |
| US-20020062028-A1 | Process for water soluble azole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2002-05-23 | — | — | US | disclosed |
| US-6362172-B2 | (DIHYDROGEN PHOSPHONOXY)ALKYLOXY CONTAINING A TRIAZOLE DERIVATIVE USED AS ANTIFUNGAL AGENT | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-26 | — | — | US | disclosed |
| US-20010041691-A1 | Water soluble prodrugs of azole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2001-11-15 | — | — | US | disclosed |
| US-20010016662-A1 | Water-soluble prodrugs of azole compounds | GOLIK JERZY (US) | 2001-08-23 | — | — | US | disclosed |
| US-20010014742-A1 | Water-soluble prodrugs of azole compounds | GOLIK JERZY (US) | 2001-08-16 | — | — | US | disclosed |
| WO-2001052852-A1 | WATER SOLUBLE PRODRUGS OF AZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-07-26 | — | — | WO | disclosed |
| US-6235728-B1 | FUNGICIDES | BRISTOL-MYERS SQUIBB COMPANY | 2001-05-22 | — | — | US | disclosed |
| US-5310648-A | Polymer-metal chelate compound | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1994-05-10 | — | — | US | disclosed |
| WO-1992013447-A1 | TEMPLATE POLYMERIZATION USING METAL CHELATES AND FLUID IMPRINT MATRICES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1992-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016662-A1 | Water-soluble prodrugs of azole compounds | ERG28, ASNS, WNK1 | LMNA 3697/4885FDPS 391/4885CA2 972/4885 |
| US-20010014742-A1 | Water-soluble prodrugs of azole compounds | ERG28, ASNS, WNK1 | LMNA 3697/4885FDPS 391/4885CA2 972/4885 |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | BCL2, BCL2L1, BAX | LMNA 2184/4885FDPS 1169/4885CA2 420/4885 |
| US-20150328239-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | LMNA 2184/4885FDPS 1169/4885CA2 420/4885 |
| US-20160176906-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | LMNA 2184/4885FDPS 1169/4885CA2 420/4885 |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BCL2, BAX, BCLAF1 | LMNA 547/4885FDPS 1143/4885CA2 3075/4885 |
| US-20010041691-A1 | Water soluble prodrugs of azole compounds | CYP51A1, ERG28, CYP7A1 | LMNA 4377/4885FDPS 702/4885CA2 2116/4885 |
| US-20020062028-A1 | Process for water soluble azole compounds | CYP51A1, ERG28, CYP7A1 | LMNA 4369/4885FDPS 423/4885CA2 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.